NCT02732860Recruiting
Personalized Patient Derived Xenograft (pPDX) Modeling to Test Drug Response in Matching Host
Prospective Evaluation of Freshly Implanted Cancers in Mice to Test Drug Response in Matching Host
Source: ClinicalTrials.gov · Last updated 4 May 2026
Brief summary (registry, in English)
By obtaining clinical specimens from participants with triple negative breast cancer (TNBC), colorectal cancer (CRC), high grade serous ovarian cancer (HGSOC), and other select tumor types to establish and profile as freshly implanted tumors in mice, the aim of this study is to identify agents with predicted activity in the host patient while also potentially providing them with personalized cancer treatment options
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 120 (estimated)
- First submitted
- 10 Feb 2016
- Start date
- Dec 2015
- Primary completion date
- 4 Jan 2027
- Lead sponsor
- University Health Network, Toronto
- Diseases
- Colorectal cancer, Ovarian cancer
- NCT number
- NCT02732860
What you commit to
- Study type: Observational
- Planned participants: 120
- From Dec 2015 to the primary completion date, 4 Jan 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Clinically significant hepatic, renal, cardiac or other organ dysfunction likely to limit participation in clinical trials.
- Any condition that could interfere with a patient's ability to provide informed consent such as dementia or severe cognitive impairment.
Other
- Known brain metastasis
- Any contraindication to undergoing a biopsy procedure.
Who the study is looking for
- Age \> 18 years.
- Patient diagnosis must be categorized as either (I) OR (II) OR (III) OR (IV):
- (I) Histologically confirmed Triple Negative Breast Cancer by Institutional and American Society of Clinical Oncology (ASCO)/Cancer of American Pathologists (CAP) guidelines, either:
- Stage IV (metastatic) disease that has not been treated with systemic therapy in the metastatic setting or
- Stage I to III (non-metastatic) with residual mass by clinical exam and/or breast imaging following anthracycline + taxane-containing neoadjuvant chemotherapy
- OR
- (II) Histologically-confirmed Stage IV colorectal cancer treated with ≤ 1 line of systemic therapy in the metastatic setting, either:
- Undergoing surgical resection of liver metastases or
- With metastatic lesions amenable to biopsy
- OR
- (III) Histologically-confirmed advanced High Grade Serous Ovarian Cancer, either:
- Recurrent disease with a life expectancy of at least 12 months or
- Stage III or IV with residual disease following neoadjuvant chemotherapy, or at risk of high recurrence
- OR
- (IV) Histologically confirmed solid tumor not meeting criteria for (I), (II) or (III) above, for which evaluation of investigational therapies is of particular interest or where clinical need exists, at the discretion of the PI
- Disease amenable to biopsy or surgery for tissue procurement
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Willingness and ability of patient to provide signed voluntary informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Princess Margaret Cancer Centre Coordinator of this site? Confirm its status | Toronto | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.